Aptar has announced its acquisition of Cohero Health and all of its assets, including Cohero’s HeroTracker inhaler sensors, BreatheSmart app and platform, and mSpirometer sensors. Cohero Health CEO Joe Condurso will join Aptar Pharma. Since mid-2019, Aptar has acquired a number of OINDP companies, including connected device company Sonmol, training device maker Noble International, and inhalation characterization and development companies Gateway Analytical and Nanopharm.
Cohero was founded in 2013. In December 2016, H&T Presspart and Cohero announced the launch of the eMDI, which included BreatheSmart inhaler tracking technology. In 2018, the company announced a number of new hires “to scale for growth and drive commercial sales of its BreatheSmart platform.”
Condurso said, “Cohero and Aptar are simply a great fit presenting a unique opportunity to leverage the complementary strengths of both companies. Building on our robust platform and rich innovations, we expect this combination to position us to lead the way in delivering on our joint vision, developing digital therapeutics that provide patients a better future and bring our customers stability and greater breadth of digital tools, actionable data, services and solutions. I want to recognize and thank the Cohero Health team, and express deep gratitude to each of them for their many contributions over the years, which have enabled us to carry on the vision and mission to transform respiratory care.”
Aptar Pharma VP, Global Digital Healthcare Systems Sai Shankar commented, “Cohero Health further strengthens and expands Aptar’s digital portfolio, in this case, with a focus in respiratory disease management. Aptar has made previous investments in other digital respiratory companies such as Sonmol in China and Navia Life Care in India. With this strategic bolt on, Aptar now has global capabilities to deploy digital respiratory health, utilizing either the Cohero or Aptar device portfolio/platform. The investment will also facilitate Aptar’s ability to provide diagnostic solutions in respiratory and a significant number of other disease categories.”
Aptar Pharma President Gael Touya added, “We are pleased to welcome the Cohero Health team to the Aptar Pharma family. The combination of Aptar and Cohero Health will bring additional value to our pharmaceutical customers as they seek to put more life-changing respiratory treatments and tools into the hands of empowered patients. Together, we will work toward the ultimate goal of improving patient experiences and health outcomes.”
Read the Aptar Pharma press release.
